RLMD

Relmada Therapeutics Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website relmada.com
Employees(FY) 14
ISIN US75955J4022

Performance

-12.11%

1W

-26.75%

1M

-40.25%

3M

+13.22%

6M

-19.32%

YTD

+7.74%

1Y

Profile

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Advanced Technical Analysis

Technical Analysis of RLMD 2024-05-10

Overview:

In analyzing the technical indicators for RLMD over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.

Trend An...

See more ...

Recent News & Updates

2024-05-10 20:41
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript(Yahoo Finance)
2024-05-10 20:41
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-08 18:20
Q1 2024 Relmada Therapeutics Inc Earnings Call(Yahoo Finance)
2024-05-08 15:40
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...(Yahoo Finance)
2024-05-08 09:55
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-08 04:05
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results(Prnewswire)
2024-05-05 19:30
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024(Prnewswire)
2024-03-19 22:27
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-19 18:27
Q4 2023 Relmada Therapeutics Inc Earnings Call(Yahoo Finance)
2024-03-19 08:52
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-19 05:31
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results(Yahoo Finance)
2024-03-19 04:15
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results(Prnewswire)
2024-03-11 19:30
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024(Prnewswire)
2024-03-04 18:30
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference(Prnewswire)
2024-02-01 02:02
Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares(Yahoo Finance)
2024-01-05 04:12
Health Care Roundup: Market Talk(Yahoo Finance)
2024-01-03 18:30
Relmada Therapeutics Provides Corporate Update(Prnewswire)
2023-12-28 19:47
11 Best Psychedelic Stocks to Buy in 2024(Yahoo Finance)
2023-12-20 01:39
5 Most Promising Psychedelic Stocks According to Hedge Funds (ready to review)(Insidermonkey)
2023-12-20 01:14
5 Most Promising Psychedelic Stocks According to Hedge Funds(Insidermonkey)
2023-11-10 00:57
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript(Yahoo Finance)
2023-11-08 05:47
Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results(Yahoo Finance)
2023-11-08 03:01
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results(Prnewswire)
2023-11-02 19:30
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023(Prnewswire)
2023-10-10 20:31
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting 2023(Prnewswire)
2023-10-08 19:30
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit(Prnewswire)
2023-10-05 19:30
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress(Prnewswire)
2023-09-19 20:30
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder(Yahoo Finance)
2023-08-22 19:30
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder(Yahoo Finance)
2023-08-08 04:01
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results(Yahoo Finance)

Page 1 of 4

previousnext